Edgar Filing: Protalix BioTherapeutics, Inc. - Form DEFA14A

Protalix BioTherapeutics, Inc. Form DEFA14A
October 26, 2015
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant x
Filed by a Party other than the Registrant "
Check the appropriate box:
"Preliminary Proxy Statement
"Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
"Definitive Proxy Statement
ý Definitive Additional Materials
"Soliciting Material Pursuant to §240.14a-12
Protalix BioTherapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
, g.,

Edgar Filing: Protalix BioTherapeutics, Inc. - Form DEFA14A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
x No fee required.
"Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 Title of each class of securities to which transaction applies: Aggregate number of securities to which transaction applies: Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): Proposed maximum aggregate value of transaction: Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing fo "which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing:
1) Amount Previously Paid:2) Form, Schedule or Registration Statement No:3) Filing Party:4) Date Filed:

Edgar Filing: Protalix BioTherapeutics, Inc Form DEFA14A
October 21, 2015
Dear Protalix Shareholder,
According to our latest records, we have not yet received your proxy for the important Annual Meeting of shareholders of Protalix BioTherapeutics, Inc. to be held on November 8, 2015. Your Board of Directors has unanimously recommended that shareholders return the enclosed proxy card voting FOR all of the items on the agenda.
Your vote is important, no matter how many or how few shares you may own. Even if you have already done so, please vote TODAY by telephone, via the Internet, or by signing, dating and returning the enclosed proxy card in the envelope provided to ensure that your votes are validly received prior to the Annual Meeting.
Thank you for your support.
Sincerely,
Yossi Maimon

Edgar Filing: Protalix BioTherapeutics, Inc. - Form DEFA14A

Vice President	and Chie	f Financial	Officer
----------------	----------	-------------	---------

REMEMBER:

You can vote your shares by telephone, or via the Internet.

Please follow the easy instructions on the enclosed card.

If you have any questions, or need assistance in voting

your shares, please call our proxy solicitor,

INNISFREE M&A INCORPORATED

TOLL-FREE, at 1-888-750-5834